Hematocrit: the test most likely to change your prescription

This is the test most likely to change your testosterone prescription.

What it measures

Hematocrit is the proportion of your blood volume made up of red cells, reported as a percentage. Hemoglobin measures the oxygen-carrying protein inside those cells and moves in parallel. On a report they are usually adjacent and usually tell the same story.

Why it matters on testosterone

Testosterone increases red cell production, and it does so reliably enough that a rise is expected rather than surprising. Across 51 studies pooled in a 2010 meta-analysis, testosterone raised hematocrit by a weighted mean of 3.18 percentage points (95% CI 1.35 to 5.01) and hemoglobin by 0.80 g/dL (0.45 to 1.14). Compared with placebo, the pooled relative risk of developing erythrocytosis was 8.14 (95% CI 1.87 to 35.40) across four low-risk-of-bias trials — a wide interval, but the direction is not in doubt.

It is the commonest reason testosterone therapy gets modified or stopped. That alone earns it a page.

The mechanism is genuinely understood

This is unusual in this field, so it is worth stating clearly.

In a randomized trial of 166 older men on testosterone gel, hemoglobin and hematocrit rose by 7% and 10%, erythropoietin rose 58% at one month, and hepcidin fell by about 49%. Hepcidin is the hormone that restricts iron release; suppressing it makes more iron available for red cell production. Both the erythropoietin rise and the hepcidin fall had returned toward baseline by six months even though treatment continued — the authors interpreted this as the body resetting its erythropoietin-to-hemoglobin set point rather than simply running the old system harder.

The causal step was demonstrated in mice: testosterone inhibits hepcidin transcription through the androgen receptor acting on BMP/Smad signalling, and mice engineered to overexpress hepcidin in the liver did not get the hemoglobin rise at all. That is a genuine causal demonstration rather than a correlation.

One honest complication. In a graded-dose study of 121 men, hemoglobin and hematocrit rose with dose as expected, but the changes in erythropoietin did not differ across dose groups and did not correlate with the testosterone change. Erythropoietin alone does not explain the effect.

Evidence: Established.

What the thresholds actually say

Here the reporting is consistently tidier than the source documents.

Source	Before starting	During treatment
Endocrine Society (2018)	The graded recommendation lists “elevated hematocrit” as a contraindication and attaches no number to it. Its 2010 predecessor did: >50%	Erythrocytosis defined as >54%; withhold until it normalizes, then resume at a lower dose
AUA (2018, validity confirmed 2024)	The graded statement says only to measure hemoglobin and hematocrit and counsel on the risk — no number. The supporting text describes withholding at >50%	Reduce the dose or temporarily stop at ≥54%
VA, Recommendations for Use (January 2026)	Not specified	Reduce the dose if hematocrit exceeds 51%; stop if it exceeds 54%
FDA label, testosterone gel (2025)	Check hematocrit before starting — no number	“If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable concentration” — no number

Two things follow. The 54% stopping threshold is close to universal and you can rely on it. The starting threshold is not. The Endocrine Society’s graded recommendation gives no figure, the AUA’s 50% lives in supporting discussion rather than in a graded statement, and the VA addresses only treatment.

Where societies do commit to a pre-treatment number, they land in a narrow band. The European Academy of Andrology gives 48 to 50%. The American Association of Clinical Endocrinology and the International Consultation on Sexual Medicine give 50%, as did the Endocrine Society’s own 2010 guideline. The International Society for the Study of the Aging Male gives 52%. A figure of 48% is commonly attributed to the current Endocrine Society guideline’s table of contraindications and a 2024 systematic review in the Asian Journal of Andrology tabulates it that way — but it is not in the graded recommendation, which is the part of the document carrying the Society’s formal strength rating.

The practical reading: somewhere between 48 and 52% your clinician should be pausing, and no single authoritative line exists. Anyone who quotes you one as settled is being tidier than the source documents.

Monitoring

Hemoglobin and hematocrit at 3 to 6 months after starting, then annually — the Endocrine Society and the VA agree, and the FDA label says the same.

What raises the risk

Formulation. Short-acting injectables raise hematocrit most and patches least. In a network meta-analysis of 29 placebo-controlled trials in 3,393 men, the mean rise versus placebo was 4.0 percentage points for injectable enanthate or cypionate (2.9 to 5.1), 4.3 for oral undecanoate (0.7 to 8.0), 3.0 for gel (1.8 to 4.3), 1.6 for injectable undecanoate (0.3 to 3.0) and 1.4 for the patch (0.2 to 2.6). Only injectable cypionate or enanthate versus patch differed significantly head to head; the rest of the ordering is real but not statistically separated.

A caution about the figures you will see quoted elsewhere. The widely circulated incidence numbers — 67% on injectables, 13% on gel, 35% on pellets — come from a single retrospective review of 178 men, and that paper says itself that its injectable group was more than a decade younger and started with higher hemoglobin and hematocrit. No meta-analysis of erythrocytosis incidence by formulation exists. The cleanest randomized figure comes from the T4DM trial, where 106 of 491 men (22%) on injectable testosterone undecanoate over two years crossed the 54% safety trigger, against 6 of 484 (1%) on placebo.

Sleep apnea. Independently associated, with an adjusted odds ratio of 2.09 (95% CI 1.17 to 3.76) for hematocrit at or above 52% in one cohort of 474 men. See when testosterone isn’t the answer.

SGLT2 inhibitors. Taken alongside testosterone, the adjusted odds of a new hematocrit above 54% within a year were 3.80 (2.27 to 6.11) compared with the SGLT2 inhibitor alone and 2.49 (1.51 to 3.59) compared with testosterone alone. If you take both, this is worth knowing.

Time. With transdermal treatment the rise continues for roughly the first five to six months and then plateaus. Time to cross 50% differed by route in one series — about 10.5 months on injectables, 14.0 on gel, 16.4 on pellets. In a transmasculine cohort the mean time to peak was 31 months, so “it peaks at six months” is not a universal rule.

The part that is usually overstated

You will be told that a high hematocrit on testosterone causes blood clots. The mechanism is plausible and the physiology is real. The outcome data are much thinner than the confidence with which this is asserted.

A 2018 review of the field concluded that no randomized or prospective study had observed a direct relationship between testosterone-induced erythrocytosis and thromboembolic events. A 2025 systematic review of 45 studies found exactly one retrospective study reporting increased events in treated men who developed erythrocytosis versus those who did not, and concluded that the existing literature does not suggest a clear association. In a cohort of 519 transgender patients on testosterone, 20% developed a hematocrit above 50% and five had a thromboembolic event — none of whom had erythrocytosis at the time of the event.

TRAVERSE found more pulmonary embolism, more atrial fibrillation and more acute kidney injury in the testosterone arm. That is a real finding and it belongs in the decision. But TRAVERSE actively titrated doses to keep hematocrit below 54%, so by design it cannot tell you what erythrocytosis itself does, and it did not report thrombotic events stratified by hematocrit.

Evidence: Mixed — Established that testosterone raises hematocrit, Limited that the rise causes clots.

The practical consequence is not “ignore it.” It is that the 54% threshold is a sensible precaution built on physiology rather than a line where measured risk is known to change.

Phlebotomy

Frequently offered, and the evidence behind it is weaker than most men are told. Two independent reviews in 2024 and 2025 concluded that evidence for the efficacy or safety of therapeutic phlebotomy in this setting is lacking, and both raised the possibility of net harm — phlebotomy depletes iron and lowers tissue oxygen, and in a different erythrocytosis context arterial thrombosis was more common among those who underwent it. No study has tested phlebotomy here against a clinical outcome rather than against the number on the report.

Lowering the dose, lengthening the interval, or changing formulation addresses the cause. Phlebotomy addresses the measurement.

Evidence: Limited.

Related

Testosterone, the prostate and the heart · Testosterone replacement therapy · The Lab Library · Total testosterone

Questions patients ask